Experimental drug found to improve symptoms of generalized myasthenia gravis
Argenx, a Belgian drug maker, recently announced a successful phase 3 ADAPT trial of its experimental drug, efgartigimod. The company plans to seek U.S. approval of the drug by the end of year as a potential new treatment ...
May 29, 2020
0
12